Abstract: A computer based system and method for designing an automotive vehicle orients an occupant representation, in electronic form, with respect to a three-dimensional electronic representation of a portion of the vehicle. At least one vehicle system is represented, also in electronic form, with respect to a common reference point, at least one human factors study is electronically performed to determine occupant interaction with at least one vehicle system, and an outcome of that study is reported to a vehicle designer. The designer then has an option to vary, or alter, the occupant orientation, the location of the vehicle system, or both, so that the design meets a predetermined criteria of the study. However, the designer may opt to retain the design despite non-compliance with the criteria.

Abstract: A method and system which combines a properly designed FEC and the periodic transmission of known symbols to obtain a desired error performance in a point-to-multipoint digital transmission system employing a DFE which induces error propagation. A transmitter unit includes a forward error correction encoder (FEC) which implements a code to information provided to an input of a data interleaver having block length N and interleaving depth D, and a data modulator which is coupled to an output of the data interleaver to receive a stream of data symbols. At least one receiver unit includes a decision feedback equalizer (DFE) which includes a feedback filter and provides an input to a data deinterleaver having block length N and interleaving depth D, and a FEC decoder which receives data from an output of the data deinterleaver. Sequences of known symbols of length at least equal to the length of the feedback filter are periodically added to the output of the data interleaver.

Abstract: An apparatus is programmed with a plurality of programming instructions for automatically generating a reconfiguration script comprising a plurality of configuration commands for reconfiguring a plurality of telecommunication devices of a telecommunication system, based on a current and a target descriptive image of the telecommunication system. The current descriptive image specifies the devices and their features included in the current configuration of the telecommunication system, whereas the target image specifies the devices and their features to be included in the target configuration of the telecommunication system. The plurality of programming instructions generate the reconfiguration script employing feature dependency graph (FDG) data structures, a device model modeling the rules and behaviors of the telecommunication devices, and feature deletion/addition linklists.

Abstract: A forward error correction (FEC) system and method for use in a multipoint-to-point frame based synchronized transmission communication system in which data from users are sent in selected portions of data frames having coded symbols added thereto by encoders associated with each user. The number of bits per user assigned portions of data frames is established as an integer number of FEC code symbols. The interleaving depth is set equal to a multiple of the total number of code symbols sent by a user in a data frame. The encoders are synchronized such that all of the encoders start processing associated interleaving frames at the same time. In exemplary embodiments, the communication systems include DWMT and TDM communication systems.

Abstract: The present invention relates to a class of compounds represented by Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: A time-dependent piecewise linear signal generating circuit includes a first circuit responsive to a trigger signal to provide a number of time region signals each corresponding to a separate predefined time window of the piecewise linear signal, and a second circuit responsive to some of the time region signals to produce slope signals corresponding thereto, wherein each of the slope signals define a slope of the piecewise linear signal during a respective one of the time windows. A third circuit is responsive to the slope signals and the time region signals to produce the piecewise linear signal.

Abstract: A cross-coupled latch circuit that is a one-time programmable latch that allows volatile temporary writes to the latch prior to permanent programming of the latch. The latch circuit includes first and second programmable FET devices that include poly-poly capacitators in series with the gate terminal of each device. A pair of PMOS FET devices combine with the programmable devices to make up the latch. The latch circuit includes other FET devices that are switched on and off depending on whether the latch is being permanently programmed, temporarily written to, or reset. A NAND gate is provided such that a logical high output on the NAND gate allows the first programmable device to be temporarily programmed with a logical one and permanently programmed with a logical zero. A NOR gate is provided such that a logical high on the NOR gate allows the second programmable device to be temporarily programmed with a logical zero and permanently programmed with a logical one.

Abstract: The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

Abstract: A receiver for transmitted signals which represent digital symbol values includes a low-pass filter to minimize transmission noise by reducing the receiver bandwidth. However, this creates pulse distortion which can cause intersymbol interference when the filtered signal is supplied to a symbol detector. Such interference is minimized by the inclusion of a feedback loop between the output of the symbol detector and the input to the filter, in which a detected symbol is multiplied by correction factor and supplied to a subtractor where it is subtracted from the signal to be filtered. The result of the subtraction is supplied to the filter. The noise reduction filter is thus also used for matching the intersymbol distortion characteristic of a filtered detected symbol to the intersymbol distortion characteristic of a filtered received signal pulse.

Abstract: A data transmission system including a telephone service subscriber loop utilized for transmission of data including telephone service signals; a splitter operable for splitting the subscriber loop into a first transmission path including a low pass filter which accommodates a continuation of telephone service signal transmissions along the subscriber loop and a second transmission path, said second transmission path including a capacitive element for attenuating the telephone service signals; and a digital subscriber loop transceiver coupled to the second transmission path for implementing high rate digital data transmission over the subscriber loop, the transceiver including a frontend processing circuit having a transmit path and a receive path, at least said receive path comprising a high pass filter for further attenuating said telephone service signals.

Abstract: A compiler is provided to a network element management subsystem for compiling rules and behaviors of device types into nested meta data structures of model databases. The rules and behaviors of the device types are specified via definitions describing controls of the device types, and features assignable to the device types. In one embodiment, the compiler is a two phase compiler comprising a parsing and list building phase and a database building phase. The device type model databases are loaded into memory to allow fast access and traversal. Each of the model databases comprises a plurality of nested meta data structures. Data are conditionally retrieved by selectively traversing the model databases using navigation sequences. An array of evaluation functions is further provided to evaluate predicates embedded in the nested meta data structures in view of operational data. During operation, user and system actions are interpreted through device emulation accessing the appropriate model databases.

Abstract: The present invention provides compounds of the formula Ar.sup.1 --Q--Ar.sup.2 --Y--R--Z and pharmaceutically acceptable salts thereof wherein Ar.sup.1 and Ar.sup.2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB.sub.4 production, such as psoriasis, ulcerative colitis, IBD and asthma.

Abstract: For avoiding error propagation as a result of decision feedback equalization, the data to be transmitted are coded with a coder 2 which has a transfer function substantially inverse to the transfer function of the channel 4. Consequently, instantaneous decisions about the received symbol may be made at the receiver 6 without intersymbol interference causing a disturbance. If the channel transfer function differs from the transfer function of the precoder 2, intersymbol interference will again occur, so that the symbol error rate will increase. In order to restrict this increase of the symbol error rate as much as possible, the receiver comprises a cascaded circuit of an adaptive filter 18 which has an inverse transfer function to that of the channel and a decoder 21 which has an inverse transfer function to that of the precoder 2.

Abstract: The present invention relates to compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2;wherein R is H or lower alkyl of 1 to 6 carbon atoms;wherein X is selected from the group consisting of hydrogen, methane sulfonamide, nitro, cyano, imidazolyl, alkoxy of 1 to 6 carbon atoms and hydroxy; andwherein Ar is selected from the group consisting of pyridinyl and benzofuranyl optionally substituted by methane sulfonamide, nitro, cyano, or imidazolyl with the proviso that when n is 1, Ar is other then phenyl;pharmaceutical compositions containing these compounds and a method for treating cardiac arrhythmias in mammals by administering the compositions.

Abstract: Non-peptidyl compounds characterized generally as quinolinyl/quinolinylalkyl-N-terminal amino hydroxy .beta.-amino acid derivatives are useful as renin inhibitors for treatment of hypertension. Compounds of particular interest are of the formula ##STR1## wherein R.sub.1 is selected from ##STR2## wherein each of Y and Z is independently selected from hydrido, chloro, fluoro, methoxy and dimethylamino; wherein n is a number selected from zero through four, inclusive; wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and methyl; wherein R.sub.3 is methyl or ethyl; wherein R.sub.5 is cyclohexylmethyl; wherein R.sub.6 is hydroxy; and wherein R.sub.7 is isobutyl or ethyl; or a pharmaceutically-acceptable salt thereof.

Abstract: The present invention relates to compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof; wherein n is 0, 1 or 2;wherein R is H or lower alkyl of 1 to 6 carbon atoms;wherein X is selected from the group consisting of hydrogen, methane sulfonamide, nitro, cyano, imidazolyl, alkoxy of 1 to 6 carbon atoms and hydroxy; andwherein Ar is selected from the group consisting of pyridinyl, tetrahydronaphthalenyl, benzofuranyl, and Ph--CH.dbd.CH-- and phenyl all optionally substituted by methane sulfonamide, nitro, cyano, or imidazolyl with the proviso that when n is 1, Ar is other then phenyl;pharmaceutical compositions containing these compounds and a method for treating cardiac arrhythmias in mammals by administering the compositions.

Abstract: Non-peptidyl compounds characterized generally as chromonyl/chromonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy .beta.-amino acid derivatives are useful as renin inhibitors for treatment of hypertension. Compounds of particular interest are of the formula ##STR1## wherein R.sub.1 is selected from ##STR2## wherein each of Y and Z is independently selected from hydrido, chloro, fluoro, methoxy and dimethylamino; wherein n is a number selected from zero through four, inclusive; wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and methyl; wherein R.sub.3 is methyl or ethyl; wherein R.sub.5 is cyclohexylmethyl; wherein R.sub.6 and R.sub.7 are taken together to form a partially saturated or fully saturated heterocyclic ring containing five to eight ring members with one or two ring members being oxygen atoms and the remaining ring members being carbon atoms, and which heterocyclic ring may be optionally substituted with lower alkyl; or a pharmaceutically-acceptable salt thereof.